Literature DB >> 8786290

Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.

S Ehl1, U Hoffmann-Rohrer, S Nagata, H Hengartner, R Zinkernagel.   

Abstract

To address the question of whether cytotoxic CD8+ T cells (CTL) activated in vivo are susceptible to cell death mediated by CD95 (Fas/Apo-1) ligand, a recombinant vaccinia virus expressing murine CD95L (vacc CD95L) was constructed, which drives CD95L expression to infected cells. T cells contacting virus-infected cells during priming, killing, or restimulation therefore encounter CD95L on the same cells. CD95L expression in vivo after infection with the vaccinia recombinant was sufficient to induce extensive necrosis in the liver of normal but not of CD95 mutant lpr mice. Fibroblast cell lines infected with this virus specifically killed CD95-transfected target cells and in vitro activated T cells. In contrast, when T cells were activated by a viral infection in vivo, they were not susceptible to CD95L-mediated cell death during the induction, effector, or memory phase in vitro or in vivo. These results suggest no direct role for CD95L in regulating CTL responses in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786290

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Differences in the regulation of CD4 and CD8 T-cell clones during immune responses.

Authors:  P C Beverley; M K Maini
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

2.  The Bcl-2 family pro-apoptotic molecule, BNIP3 regulates activation-induced cell death of effector cytotoxic T lymphocytes.

Authors:  J Wan; D Martinvalet; X Ji; C Lois; S M Kaech; U H Von Andrian; J Lieberman; R Ahmed; N Manjunath
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

3.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

Authors:  D B Chappell; T Z Zaks; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

4.  Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.

Authors:  Jie-Hui Li; Dalia Rosen; Paul Sondel; Gideon Berke
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

5.  Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction.

Authors:  S Qian; L Lu; F Fu; Y Li; W Li; T E Starzl; J J Fung; A W Thomson
Journal:  J Immunol       Date:  1997-05-15       Impact factor: 5.422

6.  The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells.

Authors:  I Suzuki; P J Fink
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 7.  The relative role of lymphocyte granule exocytosis versus death receptor-mediated cytotoxicity in viral pathophysiology.

Authors:  M J Smyth; J A Trapani
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 8.  Death receptor-ligand systems in cancer, cell death, and inflammation.

Authors:  Henning Walczak
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-05-01       Impact factor: 10.005

9.  Prolongation of corneal allograft survival by CTLA4-FasL in a murine model.

Authors:  Weiyun Shi; Min Chen; Lixin Xie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-05-31       Impact factor: 3.117

Review 10.  Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.

Authors:  Sergio A Quezada; Karl S Peggs; Tyler R Simpson; James P Allison
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.